Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Credit agrmnt [a]
Appointed director
Athenex, Inc. (ATNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/18/2023 8-K Quarterly results
07/10/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
05/23/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/03/2023 8-K Quarterly results
04/28/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/25/2023 8-K Quarterly results
03/31/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment No. 1 to the Amended and Restated Bylaws of Athenex, Inc",
"Amendment No. 1 to the Amended and Restated Bylaws of Athenex, Inc"
03/20/2023 10-K Annual Report for the period ended December 31, 2022
03/20/2023 8-K Quarterly results
02/14/2023 SC 13D/A LAU JOHNSON YIU NAM reports a 4.8% stake in ATHENEX, INC.
02/14/2023 8-K Quarterly results
02/02/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
12/09/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/22/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
10/11/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/11/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/03/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
09/16/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/18/2022 8-K Quarterly results
08/12/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Harter Secrest & Emery LLP",
"Underwriting Agreement, by and between the Company and SVB Securities LLC",
"Form of Pre-Funded Warrant",
"Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants BUFFALO, N.Y., August 10, 2022 — Athenex, Inc. , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the shares of common stock, warrants and pre-funded warrants are being offered by Athenex. SVB Securities is acting as sole book-running manager for the offering. The offering is ...",
"Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants BUFFALO, N.Y., August 11, 2022 — Athenex, Inc. , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of its underwritten public offering of 35,333,334 shares of its common stock and accompanying warrants to purchase up to 35,333,334 shares of common stock at a combined public offering price of $0.75 per share and accompanying warrant and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 4,666,666 shares of its common stock and accompanying warrants to purchase up to 4,666,666 shares of common stock at a combined public off..."
08/12/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/10/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/29/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/28/2022 8-K Quarterly results
07/11/2022 8-K Quarterly results
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/01/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy